Skip to main content
Qiagen N.V. logo

Qiagen N.V. — Investor Relations & Filings

Ticker · QIA ISIN · NL0015001WM6 LEI · 54930036WK3GMCN17Z57 F Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2019-07-31 Earnings Release
Country NL Netherlands
Listing F QIA

About Qiagen N.V.

https://www.qiagen.com/

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Recent filings

Filing Released Lang Actions
QIAGEN reports full results for second quarter and first half of 2019
Earnings Release Classification · 100% confidence The document explicitly states: "QIAGEN reports full results for second quarter and first half of 2019" and provides detailed financial tables for Q2 2019 and H1 2019, including Net Sales, Operating Income, EPS, and Balance Sheet/Cash Flow data. This content structure—comprehensive financial reporting for a period shorter than a full year (Q2 and H1)—is characteristic of an Interim/Quarterly Report. While it contains elements of an Earnings Release (ER) by summarizing key figures, the depth of the tables and narrative analysis (e.g., detailed segment breakdowns, balance sheet review) pushes it beyond a simple ER announcement into the category of a comprehensive Interim Report (IR). It is not a 10-K (Annual Report) because it covers only Q2/H1. Q2 2019
2019-07-31 English
Ad hoc Announcement according to Art. 17 Market Abuse Regulation - QIAGEN’s Q2 2019 results in line with CER outlook, revised 2019 outlook due to intended restructuring of China NGS partnership
Earnings Release Classification · 100% confidence The document is titled "QIAGEN reports results for second quarter of 2019" and provides detailed financial figures (net sales, adjusted EPS, operating income) specifically for the second quarter of 2019. It also updates the outlook for the full year 2019. This content structure—reporting on a specific, shorter fiscal period (quarterly) with detailed financial metrics—is characteristic of an Interim/Quarterly Report (IR). Although it mentions that full results will be released later (July 30), this specific document serves as an initial announcement summarizing the key performance indicators for the quarter, which aligns closely with the definition of an Earnings Release (ER). However, since it contains substantial detail beyond just highlights (including segment breakdowns and balance sheet/income statement line items implied by the metrics), and given the context of a major company reporting on a specific period, it functions as a comprehensive quarterly update. Since 'IR' is defined as a 'Comprehensive financial report for a period shorter than a year (e.g., half-year)', and this document details Q2 results, IR is the most appropriate classification over ER (which is defined as 'Initial announcement... key highlights only'). The document is not a mere announcement of a report (RPA) because it contains the actual results. Q2 2019
2019-07-25 English
Ad hoc Announcement according to Art. 17 Market Abuse Regulation - QIAGEN’s Q2 2019 results in line with CER outlook, revised 2019 outlook due to intended restructuring of China NGS partnership
Earnings Release Classification · 100% confidence The document is explicitly titled as an "Ad hoc Announcement according to Art. 17 Market Abuse Regulation" and provides key financial highlights for Q2 2019, including net sales growth and adjusted EPS, along with a revised full-year 2019 outlook. This structure—a brief, immediate announcement of key financial performance metrics and forward-looking guidance changes—is characteristic of an Earnings Release (ER). It is not a full report (10-K or IR) nor a transcript (CT). The short length (1794 chars) and focus on immediate results confirm it is an initial release, not a detailed report. Q2 2019
2019-07-25 English
6-K
Regulatory Filings
2019-07-24 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-06-07 English
6-K
Regulatory Filings
2019-05-07 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.